Justices Experiment With Enablement Paths In Amgen IP Row
The U.S. Supreme Court justices on Monday seemed confused as they grappled for more than an hour and a half over how many antibodies are actually covered by Amgen patents underlying...To view the full article, register now.
Already a subscriber? Click here to view full article